The bone mineral density of hip joint was reduced in the initial stage of ankylosing spondylitis?

Peng Li Cai, MD, Yun Yu Yan, MD, Wei Wei, BD, Xiao Shuai Chen, Jian Zhao, PhD, Ze Kun Zhang, MD, Ping Zhang, PhD*

Abstract

The osteoporosis was common complication of ankylosing spondylitis (AS), but it was frequently unrecognized in the initial stage of the disease. This study was to compare areal bone mineral density (BMD) of hip joints in early AS patients with that in healthy controls, to explore the progress of bone loss in cortex and spongiosa in early AS.

Quantitative computed tomography (QCT) of hip was performed in 60 AS patients (modified New York criteria for AS, with grade 2 sacroiliitis in computed tomography) and 57 healthy controls. The QCT measurements of AS patients were compared with the measurements of healthy controls.

The AS patients had lower areal BMD in cortical bone and total bone of proximal femur in early AS patients ($P<0.01$), than the controls. But there were not significant different of areal BMD in spongiosa of proximal femur between the early AS patients and healthy controls. Strong correlations were found between body mass index (BMI), areal BMD in cortical bone ($r_s=0.410, P<0.001$; $r_s=0.422, P<0.001$) and total bone ($r_s=0.368, P<0.001$; $r_s=0.266, P=0.003$) both in AS patients and healthy controls.

The results indicate that osteopenia/osteoporosis is general in early stage of AS. What is more, the osteopenia/osteoporosis in cortex is earlier than in spongiosa of proximal femur in early AS.

Abbreviations: AS = ankylosing spondylitis, BMD = bone mineral density, BMI = body mass index, QCT = quantitative computed tomography.

Keywords: ankylosing spondylitis, bone mineral density, cortex, osteopenia, osteoporosis, spongiosa

1. Introduction

Ankylosing spondylitis (AS) is an inflammatory disease, with new bone formation and ossification of the ligamentous apparatus as the primary pathological changes. The osteoporosis is coexisting with new bone formation, becoming the early feature of AS, particularly pronounced in active disease.[1–3] The mechanisms of inflammation, new bone formation and osteopenia/osteoporosis in AS are incompletely understood. The inflammation may play a dominant role in early AS,[1,4] and low bone mineral density (BMD) of the lumbar spine and femoral neck is accompanying with inflammation in early AS and mild disease.[5] In late AS, ankylosis of joints result in decreased mobility inducing disuse osteoporosis.[6] In the past few decades, the data measured by dual-energy X-ray suggested that the inflammation may be an etiologic factor of bone loss in AS.[7,8] At present, there are a lot of different methods for monitoring the BMD in AS.[9–11]

Osteoporosis is well known a common complication in AS. Low BMD of femoral neck has been observed in early AS, while the bone loss begins from the cortex or the spongiosa is unknown. Our aim is to investigate the progress of bone loss in cortex and spongiosa by quantitative computed tomography (QCT) in early AS, compared with the health controls in similar age.

2. Methods

2.1. Participants

From October 2016 to January 2018, 60 patients (44 men and 16 women, age range 19 to 45 years, mean age 29.6 years) were recruited from the rheumatic immunity clinic. The inclusion criteria were AS according to modified New York criteria, and age more than 18 years old. What was more, the sacroiliitis was grade 2 in computed tomography (CT), that was small localized area with...
Demographic multivariable linear regression analysis assessing AS patients with an independent predictor of areal BMD.

Clinical characteristics and areal BMD of AS patients and health controls.

|                         | Control group | AS group | P value |
|-------------------------|---------------|----------|---------|
| Demographic             |               |          |         |
| Male%                   | 68.4%         | 75%      | .68     |
| Age, yr                 | 32.5 ± 10.3   | 29.6 ± 7.7 | .09  |
| BMI (kg/m²)             | 24.1 ± 3.6    | 23.7 ± 3.6 | .55   |
| Cortical bone (g/cm²)   |               |          |         |
| femoral neck            | 0.47 ± 0.16   | 0.39 ± 0.13 | .00  |
| femoral trochanter      | 0.27 ± 0.11   | 0.20 ± 0.07 | .00  |
| femur intertrochanter   | 0.77 ± 0.17   | 0.68 ± 0.16 | .00  |
| Total                   | 0.56 ± 0.12   | 0.47 ± 0.11 | .00  |
| Spongy bone (g/cm²)     |               |          |         |
| femoral neck            | 0.38 ± 0.13   | 0.38 ± 0.13 | .88  |
| femoral trochanter      | 0.41 ± 0.07   | 0.40 ± 0.07 | .31  |
| femur intertrochanter   | 0.33 ± 0.06   | 0.33 ± 0.06 | .66  |
| Total                   | 0.36 ± 0.05   | 0.36 ± 0.06 | .84  |
| Total bone (g/cm²)      |               |          |         |
| femoral neck            | 0.88 ± 0.20   | 0.80 ± 0.19 | .00  |
| femoral trochanter      | 0.68 ± 0.13   | 0.60 ± 0.11 | .00  |
| femur intertrochanter   | 1.09 ± 0.17   | 1.01 ± 0.18 | .00  |
| Total                   | 0.92 ± 0.14   | 0.85 ± 0.22 | .005 |

AS = ankylosing spondylitis, BMD = bone mineral density.

erosion or sclerosis, without alteration in the joint width. Exclusion criteria were psoriasis, inflammatory bowel disease, dementia, pregnancy, joint surgery, and intraarticular injection. All of the patients had suffered from 2 or more of the following symptoms: insidious onset of pain/discomfort, morning stiffness, improvement of symptoms with exercise, or pain at night. None of the patients was treated with tumor necrosis factor α inhibitors or other biologic agents during the 3 months preceding the examination. Fifty-seven health controls (39 men and 18 women, age range 19 to 45 years, mean age 31.8 years) were collected.

2.2. Equipment and scanning techniques

All patients and health controls underwent hip QCT examinations, performed by the same radiologist who had > 5 years of work experience. All subjects were scanned using CT (Somatom Sensation 16, Siemens, Erlangen, Germany). The scanning parameters were as follow: 120Kv, 125mAs, 1mm slice thickness, and 500Mm field of view. QCT studies were performed using the QCT Pro calibration phantom. The scanning region was from the iliac crest to mid-thigh.

2.3. Image analysis and data collection

One musculoskeletal radiologist with more than 5 years of musculoskeletal imaging experience, blinded to the diagnosis and patient demographics, evaluated all QCT images. Features evaluated included the presence or absence of: bone sclerosis, bone cortex erosion, and hip space narrowing.

The QCT allows measurement of areal BMD measured in g/cm² and volumetric BMD measured in mg/cm³. In order to better measure cortical BMD, areal BMD was adopted as the quantitative parameter. Quantitative parameters were included as follow:

(1) Areal BMDs of cortex at femoral neck, tuberosity, intertrochanteric, and total hip;
(2) Areal BMDs of spongiosa at femoral neck, tuberosity, intertrochanteric, and total hip;
(3) Areal BMDs of bones at femoral neck, tuberosity, intertrochanteric, and total hip.

2.4. Statistical analysis

We summarized categorical and continuous variables as frequencies (percentages) and means (standard deviations) respectively. Two-sample t tests, or chi-square tests were used to compare intergroup differences. Multivariable linear regression analysis (adjusted for sex, age and body mass index [BMI]) was performed to study the effect of AS and health control on QCT parameters. We also examined the association between BMI and bone parameters using Pearson or Spearman correlation coefficients. A P value < .05 was considered statistically significant. The study was approved by institutional research ethics board. All subjects gave written informed consent.

3. Results

No statistically significant differences were identified between the AS patients and health controls with respect to age, sex, and BMI (Table 1). In 60 patients with AS, none had bone sclerosis, bone cortex erosion, and hip space narrowing. The disease durations of the patients were less than 5 years. There were 5 patients with peripheral joint involvement.

Intergroup comparisons performed using 2-sample t tests showed that AS patients had significant bone loss of areal BMD in cortical bones and total bones compared with the health controls. No statistically significant differences were identified between the AS patients and health controls with respect to areal BMD in spongy bones (Table 1).

Multivariable linear regression analyses assessing AS and health control with an independent predictor of areal BMD were shown in Tables 2 and 3. The BMI showed statistically significant positive correlations with the areal BMD of cortical bone and total bone of hip both in AS patients and health controls. The areal BMD of spongy bone showed statistically significant correlations with sex, age, and BMI in AS patients, but only showed statistically

| Table 2 |
|---------|

Multivariable linear regression analysis assessing AS patients with an independent predictor of areal BMD.

| QCT          | Adj R² | P value | sex t | P  | age t | P  | BMI t | P  |
|--------------|--------|---------|-------|----|------|----|------|----|
| Cortical bone| 0.167  | .000    | 1.179 | .241| -0.004| .997| 4.057| .000|
| Spongy bone  | 0.191  | .000    | 3.611 | .000| -3.959| .000| 2.189| .031|
| Total bone   | 0.088  | .003    | 1.805 | .074| -1.409| .162| 2.813| .006|

The model was adjusted for differences in sex, age, and BMI. Adj = adjusted, AS = ankylosing spondylitis, BMD = bone mineral density, BMI = body mass index, QCT = quantitative computed tomography.
significant correlations with sex in health controls. The areal BMD of total bone showed statistically significant correlations with sex, age, and BMI in health controls, but only showed statistically significant correlations with BMI in AS patients.

Strong correlations were found between BMI, areal BMD in cortical bone ($r_s = 0.410, P < .001; r_s = 0.422, P < .001$) and total bone ($r_s = 0.368, P < .001; r_s = 0.266, P = .003$) both in AS patients and healthy controls (Figs. 1 and 2).

---

**Table 3**

Multivariable linear regression analysis assessing health controls with an independent predictor of areal BMD.

| OCT            | Adj. $R^2$ | P value | Sex | Age | BMI |
|----------------|------------|---------|-----|-----|-----|
| Cortical bone  | 0.175      | .000    | 1.177 | .242 | -1.456 | .148 | 4.762 | .000 |
| Spongy bone    | 0.085      | .000    | 2.966 | .004 | -1.734 | .086 | 0.639 | .524 |
| Total bone     | 0.198      | .000    | 2.333 | .021 | -2.309 | .023 | 0.369 | .000 |

The model was adjusted for differences in sex, age and BMI.

Adj = adjusted, BMD = bone mineral density, BMI = body mass index. QCT = quantitative computed tomography.
4. Discussion

The osteoporosis is a common complication of AS. High disease activity and hip involvement are the risk factors of bone loss in patients with AS. Patients with AS are at high risk of vertebral fractures, but not significant at risk of hip fractures, compared with controls. Longitudinal study in early AS has suggested that spine and hip BMD decrease in early AS, especially in inflammatory activity stage. Our results suggested that AS patients in early stage had lower cortical areal BMD and total areal BMD at hip joints, compared with the health controls. There was no significant difference of areal BMD in spongy bones of hip joints between AS patients and health controls. This was similar to the early study of QCT about BMD of AS patients. It reported that the bone density of the spongiosa was reduced in early AS, but this was not significant for the study group. This study conducted that reduction of cortical bone was evident parallel to spongiosa loss, and then in advanced stages, the cortical bone tended to increase because of the ankylosis. There was not a definite answer about whether the cortical bone is firstly involved in early AS or is parallel to the spongiosa loss? Our study seems to support that the cortical bones tend to firstly decrease in early AS. Possible immobilization, especially in the initial inflammatory activity phases of AS, is 1 reason for bone loss in the early stage of AS. The mechanisms behind inflammation, bone loss and new-bone formation in AS are incompletely understood. A previous study approved that the excess of adipose tissue in obesity may have immunomodulating properties and pharmacokinetic consequences. It is already well known that the correlation between BMD and BMI. In this study, the BMI showed statistically significant positive correlations with the areal BMD of cortical bone and total bone of hip both in AS patients and health controls. While, related studies approved that the BMI did not influence the AS disease activity in axial spondyloarthritis. A high BMI positively correlated with syndesmophyte, but negatively influenced the response to infliximab in AS. In this study, the areal BMD of spongiosa bone showed statistically significant correlations with sex, age, and BMI in AS patients. The areal BMD of total bone showed statistically significant correlations with BMI in AS patients.

The main limitations of this study included the cross-sectional design, small sample size, and lack the data of indices of disease activity and physical activity. Despite the small size of our study, it is the largest study of areal BMD of hip joints of early AS patients (including both men and women). Our results may guide further research on the prediction and management of bone loss in initial AS patients.

5. Conclusions

We conclude that the bone loss of hip joint is distinct in early AS. What is more, the bone loss in the cortex of hip joints is earlier than spongiosa in early AS. The BMI is an important factor for the areal BMD of the AS patients and health controls.

Acknowledgments

We thank for the patients who agree us to use their image and clinical data.

Author contributions

Data curation: Peng Li Cai.
Funding acquisition: Ping Zhang.
Investigation: Ze Kun Zhang.
Resources: Wei Wei.
Software: Yun Yu Yan.
Visualization: Jian Zhao.
Writing – original draft: Xiao Shuai Chen.
Writing – review and editing: Ping Zhang.

References

[1] Briot K, Durnez A, Paternotte S, et al. Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort. Ann Rheum Dis 2013;72:1914–9.
[2] Wang DM, Zeng QY, Chen SB, et al. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases. Clin Exp Rheumatol 2015;33:465–70.
[3] Wang D, Hou Z, Gong Y, et al. Bone edema on magnetic resonance imaging is highly associated with low bone mineral density in patients with ankylosing spondylitis. PLoS One 2017;12:e0189569.
[4] Bau J, Chen Y, Yao YX. Prevalence and risk factors of low bone mineral density in juvenile onset ankylosing spondylitis. Calcif Tissue Int 2014;95:108–11.
[5] Deminger A, Klingberg E, Lorentzon M, et al. Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 3-year prospective study. Arthritis Res Ther 2017;19:273.
[6] Karberg K, Zoehling J, Sieper J, et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290–8.
[7] Gratacos J, Collado A, Pons F, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 1999;42:2319–24.
[8] Maillefert J, Aho LS, El Maghraoui A, et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001;12:605–9.
[9] Schreiber JJ, Anderson PA, Hsu WK. Use of computed tomography for assessing bone mineral density. Neurosurg Focus 2014;37:E4.
[10] Williams KD, Blangero J, Mahaney MC, et al. Axial quantitative ultrasound assessment of pediatric bone quality in eastern Nepal. Osteoporos Int 2015;26:2319–28.
[11] Klingberg E, Lorentzon M, Gothlin J, et al. Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes. Arthritis Res Ther 2013;15:R179.
[12] van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
[13] Pray C, Feroz NI, Nigil Haroon N. Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int 2012;91:182–92.
[14] Lange U, Kluge A, Strunk J, et al. Ankylosing spondylitis and bone mineral density—what is the ideal tool for measurement? Rheumatol Int 2005;26:115–20.
[15] Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71–87.
[16] Babu Vargas R, van den Berg R, van Lunteren M, et al. Does body mass index (BMI) influence the ankylosing spondylitis disease activity score in axial spondyloarthritis?: Data from the SPACE cohort. RMD Open 2016;2:e000283.
[17] Ozturk M, Allanore Y, Tulbach F, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 2012;14:R115.
[18] Kim SK, Choe CY, Lee SS, et al. Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: data from the Korean College of Rheumatology BIOlogics (KORBIO) registry. Mod Rheumatol 2017;27:855–61.